AbbVie Inc
4AB.F
| Exchange: | F |
| Currency | Euro |
| ISIN: | US00287Y1091 |
| LEI: | FR5LCKFTG8054YNNRU85 |
| Primary Ticker: | ABBV.US |
| Fiscal Year End: | December |
| Sector: | Healthcare |
| Industry: | Drug Manufacturers - General |
| Gic Sector: | Health Care |
| Gic Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| Gic Industry: | Pharmaceuticals |
| Gic Sub Industry: | Pharmaceuticals |
| Description: | Abb Vie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. |
| Address: | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 |
| Website: | https://www.abbvie.com |
| Full Time Employees: | 50000 |
| Updated On: | 2024-11-03 |
Highlights
| Market Capitalization: | 332001280000 |
| Market Capitalization Mln: | 332001.28 |
| EBITDA: | 27156000768 |
| PE Ratio: | 71.46 |
| PEG Ratio: | 0.47 |
| Wall Street Target Price: | 127.01 |
| Book Value: | 3.83 |
| Dividend Share: | 6.2 |
| Dividend Yield: | 0.03 |
| Earnings Share: | 2.63 |
| EPS Estimate Current Year: | 12.62 |
| EPS Estimate Next Year: | 13.97 |
| EPS Estimate Current Quarter: | 3.24 |
| Most Recent Quarter: | 2024-06-30 |
| Profit Margin: | 0.09 |
| Operating Margin TTM: | 0.33 |
| Return On Assets TTM: | 0.07 |
| Return On Equity TTM: | 0.54 |
| Revenue TTM: | 55532998656 |
| Revenue Per Share TTM: | 31.41 |
| Quarterly Revenue Growth YOY: | 0.03 |
| Gross Profit TTM: | 41527000000 |
| Diluted Eps TTM: | 2.63 |
| Quarterly Earnings Growth YOY: | -0.1 |
Valuation
| Trailing PE: | 71.46 |
| Forward PE: | 17.03 |
| Price Sales TTM: | 5.97 |
| Price Book MRQ: | 53.31 |
| Enterprise Value: | 383146207901 |
| Enterprise Value Revenue: | 7.50 |
| Enterprise Value Ebitda: | 44.78 |
Shares
| Shares Outstanding: | 1766339968 |
| Shares Float: | 1763199653 |
| Percent Insiders: | 0.09 |
| Percent Institutions: | 73.47 |
Technicals
| Beta: | 0.61 |
| 52 Week High: | 188.58 |
| 52 Week Low: | 120.69 |
| 50 Day MA: | 176.49 |
| 200 Day MA: | 163.80 |
Splits & Dividends
| Forward Annual Dividend Rate: | 6.06 |
| Forward Annual Dividend Yield: | 0.03 |
| Payout Ratio: | 2.13 |
| Ex Dividend Date: | 2025-01-15 |
Earnings
| Report Date: | 2025-07-23 |
| Date: | 2025-06-30 |
| Before After Market: | After Market |
| Currency: | USD |
| Report Date: | 2025-04-24 |
| Date: | 2025-03-31 |
| Before After Market: | After Market |
| Currency: | USD |
| Report Date: | 2025-01-31 |
| Date: | 2024-12-31 |
| Before After Market: | After Market |
| Currency: | USD |
| Report Date: | 2024-10-30 |
| Date: | 2024-09-30 |
| Before After Market: | After Market |
| Currency: | USD |
| Report Date: | 2021-07-30 |
| Date: | 2021-06-30 |
| Currency: | USD |
| Eps Actual: | 3.11 |
| Eps Estimate: | 3.09 |
| Eps Difference: | 0.02 |
| Surprise Percent: | 0.64 |
| Report Date: | 2021-03-31 |
| Date: | 2021-03-31 |
| Currency: | USD |
| Eps Actual: | 2.95 |
| Eps Estimate: | 2.83 |
| Eps Difference: | 0.12 |
| Surprise Percent: | 4.24 |
| Report Date: | 2020-12-31 |
| Date: | 2020-12-31 |
| Currency: | USD |
| Eps Actual: | 2.92 |
| Eps Estimate: | 2.85 |
| Eps Difference: | 0.07 |
| Surprise Percent: | 2.45 |
| Report Date: | 2020-09-30 |
| Date: | 2020-09-30 |
| Currency: | USD |
| Eps Actual: | 2.83 |
| Eps Estimate: | 2.76 |
| Eps Difference: | 0.07 |
| Surprise Percent: | 2.53 |
| Date: | 2022-12-31 |
| Period: | +1y |
| Growth: | 0.10 |
| Earnings Estimate Avg: | 13.97 |
| Earnings Estimate Low: | 12.87 |
| Earnings Estimate High: | 14.70 |
| Earnings Estimate Year Ago Eps: | 12.62 |
| Earnings Estimate Number Of Analysts: | 17.00 |
| Earnings Estimate Growth: | 0.10 |
| Revenue Estimate Avg: | 59706800000.00 |
| Revenue Estimate Low: | 57623000000.00 |
| Revenue Estimate High: | 62354000000.00 |
| Revenue Estimate Number Of Analysts: | 18.00 |
| Revenue Estimate Growth: | 0.06 |
| Eps Trend Current: | 13.97 |
| Eps Trend7days Ago: | 13.97 |
| Eps Trend30days Ago: | 13.98 |
| Eps Trend60days Ago: | 13.95 |
| Eps Trend90days Ago: | 13.91 |
| Date: | 2021-12-31 |
| Growth: | 0.19 |
| Earnings Estimate Avg: | 12.62 |
| Earnings Estimate Low: | 12.26 |
| Earnings Estimate High: | 12.80 |
| Earnings Estimate Year Ago Eps: | 10.56 |
| Earnings Estimate Number Of Analysts: | 18.00 |
| Earnings Estimate Growth: | 0.19 |
| Revenue Estimate Avg: | 56335700000.00 |
| Revenue Estimate Low: | 55173000000.00 |
| Revenue Estimate High: | 57025000000.00 |
| Revenue Estimate Number Of Analysts: | 19.00 |
| Revenue Estimate Growth: | 0.23 |
| Eps Trend Current: | 12.62 |
| Eps Trend7days Ago: | 12.62 |
| Eps Trend30days Ago: | 12.65 |
| Eps Trend60days Ago: | 12.60 |
| Eps Trend90days Ago: | 12.57 |
| Date: | 2021-09-30 |
| Growth: | 0.14 |
| Earnings Estimate Avg: | 3.24 |
| Earnings Estimate Low: | 3.12 |
| Earnings Estimate High: | 3.32 |
| Earnings Estimate Year Ago Eps: | 2.83 |
| Earnings Estimate Number Of Analysts: | 12.00 |
| Earnings Estimate Growth: | 0.14 |
| Revenue Estimate Avg: | 14353400000.00 |
| Revenue Estimate Low: | 13813000000.00 |
| Revenue Estimate High: | 14685000000.00 |
| Revenue Estimate Number Of Analysts: | 10.00 |
| Revenue Estimate Growth: | 0.11 |
| Eps Trend Current: | 3.24 |
| Eps Trend7days Ago: | 3.24 |
| Eps Trend30days Ago: | 3.24 |
| Eps Trend60days Ago: | 3.24 |
| Eps Trend90days Ago: | 3.23 |
| Date: | 2024-09-30 |
| Eps Actual: | 6.0 |
| Date: | 2020-12-31 |
| Eps Actual: | 5.7 |